Clinicians' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.

Alexander KeenanChiara L WhichelloHoa H LeDavid M KernGabriela S FernandezVicky TurnerAnup DasMatt QuaifeAmy Perrin Ross

Published in: PharmacoEconomics - open (2024)

When considering clinical management convenience, the average US-based neurologist treating MS is likely to choose ponesimod over siponimod, fingolimod, or ozanimod. The strongest driver of preferences was the number of drug-drug interactions. This information can help inform recommendations for the treatment of MS and facilitate shared decision-making between clinicians and patients.

Keyphrases

multiple sclerosis
end stage renal disease
white matter
ejection fraction
palliative care
chronic kidney disease
newly diagnosed
ms ms
small molecule
decision making
prognostic factors
peritoneal dialysis
healthcare
emergency department
patient reported outcomes
adverse drug